Innate Pharma (IPHA) EBITDA (2019 - 2025)

Innate Pharma (IPHA) has 7 years of EBITDA data on file, last reported at -$60.9 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA fell 6.59% year-over-year to -$60.9 million; the trailing twelve-month figure through Dec 2025 stood at -$175.1 million (down 82.4% YoY), and the FY2025 full-year result was -$62.9 million, down 14.07% from the prior year.
• EBITDA for Q4 2025 stood at -$60.9 million, down from -$28.8 million in the prior quarter.
• Across five years, EBITDA topped out at $7.5 million in Q2 2021 and bottomed at -$60.9 million in Q4 2025.
• The 5-year median for EBITDA is -$28.3 million (2024), against an average of -$25.9 million.
• The widest annual swing landed in 2021, when EBITDA jumped 181.84%; it then slumped 15570.6% in 2023.
• A 5-year view of EBITDA shows it stood at -$54.7 million in 2021, then soared by 99.88% to -$64574.5 in 2022, then plunged by 15570.6% to -$10.1 million in 2023, then sank by 464.39% to -$57.1 million in 2024, then decreased by 6.59% to -$60.9 million in 2025.
• The last three EBITDA figures came in at -$60.9 million (Q4 2025), -$28.8 million (Q2 2025), and -$57.1 million (Q4 2024), per Business Quant data.

Peer Comparison